MB

Manish Boolchandani

Senior Scientist II at Empress Therapeutics

Manish Boolchandani has a diverse work experience spanning over several years. Manish is currently employed at EmpressTx as a Senior Scientist II, a position they have held since September 2022. Prior to this role, they worked as a Senior Scientist I at EmpressTx from February 2021 to August 2022.

Before joining EmpressTx, Manish worked at Washington University in St. Louis as a Graduate Student from September 2013 to December 2020. Manish gained valuable experience at Sigma Aldrich, where they held the position of Scientist from October 2009 to August 2013. Prior to this, they worked as a Scientist at Sigma Aldrich for a brief period from May 2008 to December 2008.

Manish's early work experience includes an internship at the Indian Agricultural Research Institute in Pusa, India. Manish served as an Intern from January 2007 to July 2007.

Overall, Manish has a strong background in scientific research and has consistently progressed in their career from internships to increasingly senior roles.

Manish Boolchandani pursued their education in a chronological manner. From 1994 to 2003, they attended Kendriya Vidyalaya for their primary and secondary schooling. Manish then enrolled at the University of Rajasthan, where they obtained a Bachelor of Technology (B.Tech.) degree in Biotechnology, completing their studies from 2003 to 2007. Following this, from 2007 to 2009, Manish pursued a Master of Science (MS) degree in Bioinformatics at The University of Texas at Dallas. Lastly, they completed their academic journey at Washington University in St. Louis, where they obtained a Doctor of Philosophy (PhD) degree in Computational and Systems Biology, studying from 2013 to 2020.

Location

Watertown, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Empress Therapeutics

Founded by Flagship Pioneering, Empress re-imagines the process of small molecule drug discovery. Our bioplatform harnesses the power of evolution, human molecular and genetic data, and artificial intelligence to focus on endogenous sources of inherently drug-like small molecules as a uniquely qualified source of potential drugs. Our mission is to generate transformative drug candidates that get to the clinic faster and cheaper, with a higher probability of success.


Employees

11-50

Links